Lab Members

TBA

TBA

TBA

TBA

TBA

Dr. Fischetti is Professor and Head of the Laboratory of Bacterial Pathogenesis and Immunology at the Rockefeller University, in NY. He has over 45 years of experience in the anti-infectives field, nearly all of which was spent at Rockefeller. His laboratory was the first to identify lytic enzymes as novel therapeutics to treat infections caused by the major antibiotic resistant bacterial pathogens. The first lysin against methicillin resistant S. aureus (MRSA) infections has successfully completed phase 2 clinical trials and is currently in phase 3 testing; the first antibiotic alternative to achieve this milestone. Other lysins, particularly against gram-negative pathogens, are also in the clinical development pipeline. His group was also the first to identify the LPXTG motif, necessary for attaching surface proteins on the gram-positive cell wall. This motif is now being used as a target for antibiotic development. His laboratory was responsible for elucidating the coiled-coil structure of streptococcal M protein and defining the conserved region of this molecule for a non-type-specific vaccine against S. pyogenes. Dr. Fischetti is a fellow of the American Academy of Microbiology, the National Academy of Inventors, and was the recipient of two NIH MERIT awards. He has been editor-in-chief of the scientific journal Infection and Immunity for 10 years, and serves as advisory editor for the Journal of Experimental Medicine and Trends in Microbiology among others. Dr. Fischetti serves on the scientific advisory board of Lumen Bioscience and Persica Pharmaceuticals, as well as the Trudeau institute and is also a trustee of the Trudeau Institute. He has published over 250 primary research articles, over 70 textbook chapters and has co-edited two major books on gram-positive pathogens. He is an inventor of over 40 issued patents dealing with the control of infectious diseases. Dr. Fischetti received a Ph.D. in Microbiology from New York University School of Medicine.

Ryan received his B.S. and B.A. degrees from the Pennsylvania State University in 2008, where he majored in Science and Journalism. He then obtained a Ph.D. in Molecular and Cell Biology at the University of Maryland in 2014 under the supervision of Dr. Daniel Nelson. He joined the Laboratory of Bacterial Pathogenesis and Immunology in 2014 as a Postdoctoral Associate and was elevated to the role of Research Associate in 2019. During his time in the lab, Ryan has primarily focused on developing bacteriophage lysins as novel therapeutics for the treatment and prevention of bacterial diseases.

TBA

TBA

Interested in the hypothesis that the “gut-brain axis” may play a pathogenic role in neurological diseases of unknown etiology. Multiple sclerosis (MS) and sudden infant death syndrome (SIDS) are two mysterious diseases that may benefit from a closer look at the gut-brain axis and its associated microbiome; specifically the role of gut bacterium, Clostridium perfringens, and its secreted Epsilon neurotoxin and Enterotoxin, respectively.

TBA

TBA

TBA

TBA

TBA